Mallinckrodt (MNK) PT, Estimates Updated at Piper Jaffray Following Sale of Nuclear Business

September 6, 2016 1:11 PM EDT
Get Alerts MNK Hot Sheet
Price: $45.91 -4.59%

Rating Summary:
    17 Buy, 4 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 29 | Down: 30 | New: 23
Trade MNK Now!
Join SI Premium – FREE

Get daily under-the-radar research with's Stealth Growth Insider Get your 2-Wk Free Trial here.

Piper Jaffray analyst David Amsellem updated estimates and his price target on Mallinckrodt plc (NYSE: MNK) to $105.00 (from $112.00) following the sale of the Nuclear business, but maintained an Overweight rating.

Amsellem commented, "We are revising our model to reflect the recent announcement by Mallinckrodt that it is selling its nuclear imaging business to IBA Molecular for around $690M. The transaction was not a surprise to us given that MNK had divested its contrast media business last year, and given has been aiming to free up capital to further add to its specialty brands segment via further M&A activity. We continue to believe that MNK is well positioned to deliver a long-term EPS CAGR potentially in the double digits, driven in part by sustained volume growth for Acthar (refer to our note on 8/23/16 for more details). This translates into an attractive valuation in the context of a 2017 P/E of 9x our revised EPS estimate. We reiterate our Overweight rating and are adjusting our PT to $105 from $112, reflecting the removal of the nuclear imaging business from our estimates."

For an analyst ratings summary and ratings history on Mallinckrodt plc click here. For more ratings news on Mallinckrodt plc click here.

Shares of Mallinckrodt plc closed at $72.42 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst EPS Change, Analyst PT Change

Related Entities

Piper Jaffray

Add Your Comment